F

Factor VII, 482
Factor VIIa, recombinant (NovoSeven), 485
Factor VIII, recombinant, 484
Factor IX, 482
recombinant, 484
Factor X, 482
Factor Xa inhibitors, 488
Factorial design, clinical trials, 47
Faecal elimination, 95
Faecal softeners (emollients), 540
Falciparum malaria, 229–231
False conclusions, placebo-controlled trials, 39
Famciclovir, 215
Familial combined hyperlipidaemia (FCHL), 445
treatment, 448
Familial hypercholesterolaemia (FH), 445
treatment, 448
Familial hypertriglyceridaemia (FHTG), 445
treatment, 448
Familial hypoalphalipoproteinaemia (FHA, Tangier disease), 445
treatment, 448
Famotidine, 471
Faropenem, 179
FCHL See Familial combined hyperlipidaemia (FCHL)
Febrile convulsions, 353
Febuxostat, 256
Feedback systems, 98
Felbamate, 354
Felypressin, 599
Fenofibrate, 449
Fenoterol, 474
Fentanyl, 286–287
Fenticonazole, 225
Ferritin, 497–498
Ferrous fumarate, 498t
Ferrous gluconate, 498t
Ferrous succinate, 498t
Ferrous sulphate, 498t
Fertility
oral combined contraceptive, 607
regulation, 606–611
tobacco smoking, 152
Fetal alcohol syndrome, 148
Fetus, drug effects, 120
Fever, allergic reactions, 118
FH See Familial hypercholesterolaemia (FH)
FHA See Familial hypoalphalipoproteinaemia (FHA, Tangier disease)
FHTG See Familial hypertriglyceridaemia (FHTG)
Fibrates, 449
diabetes drug interactions, 581
mode of action, 446
Fibre, soluble, 539
Fibric acid derivatives See Fibrates
Fibrin, 483
Fibrin glue, 485
Fibrinogen, 483
Fibrinolytic system, 490–492
drug prevention, 492
promotional drugs, 491–492 see also specific drugs
Filariasis, lymphatic, 237t
Filtration, cell membrane passage, 81
Finasteride, 602
benign prostatic hyperplasia, 464
First-order pharmacokinetics, 81–82
Fish tapeworm (Diphyllobothrium latum), 237t
Fixed dosage, 96
Fixed-dosage combinations
antiretroviral therapy, 220, 220t
dosing schedules, 98
human studies, 42
Fixed eruptions, 268
Fixed sample size, clinical trials, 48–49
Flavinoids, 107
Flavopiridol, 520t
Flavoxate (Urispas), 381
micturition, 464
Flecainide, 431t, 432–433
Fleming, Alexander, 162–163
Florey, Howard Walter, 163
Flucloxacillin, 175
immune-mediated drug reactions, 102t
Staphylococcus aureus endocarditis, 196
Fluconazole, 225–226
Candida infections, 223
Flucytosine, 227
Fludarabine, 515
Fludrocortisone, 563
relative potencies, 562t
Fluid resuscitation
diabetes ketoacidosis, 583
septic shock, 390
shock, 391
Fluid treatment, diarrhoea, 537
Flumazenil, 341
as antidote, 128t
Fluorinated corticosteroids, 563
Fluoroquinolones, 209
5-Fluorouracil (5FU), 515
Fluoxetine
bulimia nervosa, 318
pharmacogenetics, 104t
Flurazepam, 70
Flutamide, 512t, 602
Fluticasone, 563
asthma treatment, 476–477
Folecalcitriol, 619
Folic acid, 502–503
Folic acid antagonists, 272–273
Folic acid deficiency, 501t, 502–503
drug-induced, 503
management, 503
Folinic acid, 128t
Follicle stimulating hormone (FSH), 598
Fomepizole, 128t
Fomivirsen, 221
Fondaparinux, 489
Food(s)
monoamine oxidase inhibitor interactions, 320
pharmacokinetics, 107 See also Diet
Food and Drug Administration (FDA, USA), 63–64
Forest plots, 57, 58f
Formal therapeutic trials, 43
Formestane, 569
Formoterol, 476
Formulations, drug action prolongation, 97
Foscarnet, 221
Fosempravir, 218–219
Fosfomycin, 186
Fosfomycin trometamol, 200
Fosinopril, 400
Fosphenytoin, 357
Fractures, osteoporosis, 623
Fragments, drug discovery and development, 31
Framycetin, 181
Fuller's earth, 125
Fumarate, 368
Functional iron deficiency, 499
Fungal infections, 213, 222–227
endocarditis, 196
skin, 274–275
superficial mycoses, 223
systemic mycoses, 223 See also Mycoses specific infections
Fungal poisoning, 133
Furosemide, 454–455
ascites therapy, 550
  Page 644 
distribution volume, 90t
efficacy, 454
loop of Henle, 453–454
plasma protein binding, 91t
Fusidic acid, 547